Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

Posted on: 12 Dec 18
Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

PR Newswire

OSLO, Norway, Dec. 12, 2018

OSLO, Norway, Dec. 12, 2018 /PRNewswire/ --

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway.

The presentation provided a corporate overview, highlighting the Company's two platform technologies including clinical data from its lead pipeline asset, ONCOS-102, an oncolytic adenovirus, and the TG cancer vaccine program that targets tumors that express mutated forms of RAS - mutations known to drive cancer.

Please see the presentation attached. TRVX DNB presentation

The presentation is also available to download at


For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000

This information was brought to you by Cision,c2698730

The following files are available for download:

TRVX DNB presentation

View original content:

SOURCE Targovax

PR Newswire

Last updated on: 12/12/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.